There are 2789 resources available
1300P - A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC
Presenter: lin wu
Session: ePoster Display
1301P - Comprehensive genomic profiling (CGP) and PD-L1 IHC in patients (pts) with advanced non-small cell lung cancer (aNSCLC): Testing and treatment (Tx) patterns in the real-world (RW) setting
Presenter: Ari VanderWalde
Session: ePoster Display
1302P - Immune signatures of second-line PD-1 immune checkpoint blockade
Presenter: Kenneth O'Byrne
Session: ePoster Display
1303P - A clinical variable based nomogram could predict survival for NSCLC patients receiving atezolizumab
Presenter: Xiaoling Shang
Session: ePoster Display
1304P - Interleukin-6 (IL-6) as a potential predictive marker and a desensitizer for immunotherapy response in non-small cell lung cancer
Presenter: Yan Wang
Session: ePoster Display
1305P - Peripheral low-density neutrophils in the response to immunotherapy in untreated non-small cell lung cancer
Presenter: Hugo Arasanz
Session: ePoster Display
1306P - Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001)
Presenter: Atsushi Nakamura
Session: ePoster Display
1236P - Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
Presenter: Arsela Prelaj
Session: ePoster Display
1237P - Gut microbiome profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer
Presenter: Woraseth Saifon
Session: ePoster Display
1238P - AUTOMAN: A phase Ib/IIa study of osimertinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients
Presenter: Baohui Han
Session: ePoster Display